Kinase Inhibitor News and Research

RSS

A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.

ERES IV acquires a majority stake in Oncodesign Services

Oncodesign Services, a leading Contract Research Organization (CRO) specializing in drug discovery and preclinical services in oncology and immuno-inflammation, and Elyan Partners announce the completion of the acquisition of a majority stake in Oncodesign Services by ERES IV, representing 61.58% of its share capital, from its main shareholders, including Mr. Philippe Genne, Founder of Oncodesign Services, as well as certain key shareholders and several managers and minority shareholders, following the entry into exclusive negotiations on June 30, 2022.

From Oncodesign Services 3 Feb 2023

Multiomics analysis of kidney metabolism reveals a gatekeeper for viral infections

Our kidney filters 180 liters of blood every day and retains nutrients through a process called 'endocytosis' and through active transport in the kidney cells.

2 Dec 2022

Updated EULAR recommendations on the use of DMARDs for people with RA

Since their first publication in 2010, the EULAR recommendations for the use of disease-modifying anti-rheumatic treatments (DMARDs) in people with RA have become a most important publication in the field, and their updates are relied upon by many healthcare professionals, professional organizations and other stakeholders to offer an up-to-date and robust analysis on an optimal approach to the application of available treatment options in clinical practice.

11 Nov 2022

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Researchers have shown that the medication saracatinib shows promise as a treatment for idiopathic pulmonary fibrosis (IPF).

13 Oct 2022

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

The multitargeted tyrosine kinase inhibitor (MKI), lenvatinib, is widely used to treat advanced and metastatic thyroid cancer. However, the molecular mechanisms by which thyroid cancer cells become resistant to lenvatinib remain poorly understood. In this study, we demonstrated, for the first time, that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells.

14 Sep 2022

$Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer$

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

Researchers from The University of Texas MD Anderson Cancer Center reported study results showing that the targeted therapy fruquintinib significantly improved overall survival (OS) and progression-free survival (PFS) in patients with refractory metastatic colorectal cancer.

13 Sep 2022

Triplet therapy slows progression of advanced kidney cancer

A targeted kinase inhibitor added to a two-drug immunotherapy combination slowed the progression of advanced kidney cancer in previously untreated patients, according to research led by an oncologist from Dana-Farber Cancer Institute.

8 Sep 2022

Leukemia drug successfully disrupts HER2-positive brain metastasis in animal studies

In animal studies led by researchers at Duke Cancer Institute, a drug approved to treat leukemia successfully disrupted the ability of HER2-positive breast cancer tumors from colonizing the brain.

30 Aug 2022

New anti-cancer drug candidate is absorbed through the lymphatic system rather than blood vessels

A team of University of Michigan researchers is developing a new anti-cancer drug that is absorbed through the gut's lymphatic system rather than blood vessels, potentially outmaneuvering the molecular signaling pathways that lead to drug resistance while increasing cancer-fighting ability and reducing side effects.

17 Aug 2022

Pigment epithelium-derived factor ablations may lead to eye aging

Researchers identified that loss of pigment epithelium-derived factor (PEDF) may cause aging in the eye.

21 Jul 2022

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

Researchers introduced a phenotypic screening assay for identifying compounds with SARS-CoV-2 inhibition potential based on caspase 3/7 activation.

20 Jul 2022

The known and proposed interactions of SARS-CoV and SARS-CoV-2 with DNA damage response pathways

Researchers reviewed the consequences of infection with sSARS-CoVs on the host DNA damage response.

19 Jul 2022

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

In a recent study posted to the medRxiv* preprint server, researchers assessed the efficacy and durability of immune responses to the third dose of coronavirus disease 2019 (COVID-19) vaccines. They also assessed the efficacy of the fourth vaccine dose among severely immunocompromised patients with hematological malignancies.

7 Jul 2022

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

The University of Texas MD Anderson Cancer Center and Turning Point Therapeutics, Inc., today announced a strategic research and development alliance to expand the evaluation of two of Turning Point's investigational small molecules focusing on precision medicine targets well known in oncology.

24 Jun 2022

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Acute lymphoblastic leukemia (ALL) is the most common cancer affecting children. The T-ALL form of leukemia that emerges from early T lineage cells has a poorer prognosis than B-lineage ALL. The prognosis for relapsed T-ALL is very poor and new therapies are sorely needed.

20 Jun 2022

Kinase Inhibitor News and Research

Further Reading

ERES IV acquires a majority stake in Oncodesign Services

Multiomics analysis of kidney metabolism reveals a gatekeeper for viral infections

Updated EULAR recommendations on the use of DMARDs for people with RA

Experimental cancer drug shows promise as a treatment for idiopathic pulmonary fibrosis

Signal transduction via the EGFR pathway likely to be involved in lenvatinib resistance

Fruquintinib provides survival benefits for patients with refractory metastatic colorectal cancer

Triplet therapy slows progression of advanced kidney cancer

Leukemia drug successfully disrupts HER2-positive brain metastasis in animal studies

New anti-cancer drug candidate is absorbed through the lymphatic system rather than blood vessels

Pigment epithelium-derived factor ablations may lead to eye aging

Scientists introduce SARS-CoV-2 phenotype screening for identifying novel antiviral drugs

The known and proposed interactions of SARS-CoV and SARS-CoV-2 with DNA damage response pathways

After 3 doses of COVID vaccine, most cancer patients retain detectable humoral immunity

MD Anderson announces collaborative alliance with Turning Point Therapeutics to advance new treatment options for cancer patients

New combination of drugs effective against T-cell acute lymphoblastic leukemia

Moffitt researchers reveal a mechanism leading to drug resistance in prostate cancer

Olverembatinib a potent inhibitor of Omicron NTD-mediated cytokine release

Treatment with imatinib results in lower mortality rates for patients with severe COVID-19

Scientists identify a way to reverse drug resistance by rewiring the inner workings of leukemia cells

New tactic to disrupt cancer repair mechanism could lead to a potential treatment strategy

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News